High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

2000 • 923 citations

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

1994 • 522 citations

A new American Joint Committee on Cancer staging system for cutaneous melanoma

2000 • 438 citations

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

1997 • 302 citations

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma

2000 • 232 citations

GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.

1995 • 207 citations

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.

1998 • 162 citations

Melan-A/MART-1_51–73represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4⁺T cells

2000 • 160 citations

Ganglioside expression on human malignant melanoma assessed by quantitative immune thin‐layer chromatography

1993 • 154 citations

High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

2001 • 143 citations

Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.

1989 • 122 citations

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

2000 • 121 citations

Recognition of Shared Melanoma Antigens in Association With Major HLA-A Alleles by Tumor Infiltrating T Lymphocytes From 123 Patients With Melanoma

2000 • 121 citations

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

1998 • 112 citations

Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.

2000 • 102 citations

A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.

1999 • 97 citations

Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment

1996 • 89 citations

Neurotoxicity of interferon-? in melanoma therapy

1998 • 87 citations

Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes

2000 • 83 citations

Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.

1998 • 83 citations

Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial

1981 • 79 citations

Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases

1999 • 71 citations

Ganglioside vaccines with emphasis on GM2.

1998 • 66 citations

Interim Results of a Phase II Multicenter Clinical Trial Evaluating the Activity of a Therapeutic Allogeneic Melanoma Vaccine (Theraccine) in the Treatment of Disseminated Malignant Melanoma

1993 • 63 citations

The Majority of Autologous Cytolytic T-Lymphocyte Clones Derived from Peripheral Blood Lymphocytes of a Melanoma Patient Recognize an Antigenic Peptide Derived from Gene Pmel17/gp100

1996 • 60 citations

In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma

2000 • 58 citations

Phase III trial of melacine?? melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma

1997 • 46 citations

The large sample distribution of the weighted log rank statistic under general local alternatives.

1997 • 45 citations

Effect of IFN-α on Tumor-Infiltrating Mononuclear Cells and Regressive Changes in Metastatic Malignant Melanoma

1998 • 43 citations

Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival

1998 • 37 citations

Adjuvant Therapy for Malignant Melanoma

1981 • 23 citations

Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.

1998 • 8 citations

A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35

2000 • 5 citations

Randomized, double-blind, clinical trial of a polyvalent melanoma vaccine in patients with stage III melanoma

1998 • 3 citations

Active specific immunotherapy using attenuated autologous tumor cells in malignant melanoma

2000 • 2 citations